Selective Administration of Prophylactic Octreotide During Pancreaticoduodenectomy: A Clinical and Cost-Benefit Analysis in Low- and High-Risk Glands

Journal of the American College of Surgeons

Volumn 205, Issue 4, 2007, Pages 546-557

  Vanounou, Tsafrir ^a   Pratt, Wande B ^a   Callery, Mark P ^a   Vollmer Jr , Charles M ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OCTREOTIDE;

ADULT; AGED; ARTICLE; BLEEDING; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; DRUG EFFICACY; DUODENUM; HIGH RISK PATIENT; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MORBIDITY; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PANCREAS CYST; PANCREAS DUCT; PANCREAS FISTULA; PANCREAS ISLET CELL; PANCREAS RESECTION; PANCREATICODUODENECTOMY; PEROPERATIVE CARE; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROPHYLAXIS; RISK FACTOR; SURGEON; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; COST-BENEFIT ANALYSIS; GASTROINTESTINAL AGENTS; HUMANS; MIDDLE AGED; OCTREOTIDE; PANCREATIC FISTULA; PANCREATICODUODENECTOMY; RISK ASSESSMENT; RISK FACTORS;

EID: 34548827692     PISSN: 10727515     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jamcollsurg.2007.05.011     Document Type: Article

References (36)

1. Ho C.K., Kleeff J., Friess H., and Buchler M.W. Complications of pancreatic surgery. HPB 7 (2005) 99-108
2. Lin J.W., Cameron J.L., Yeo C.J., et al. Risk factors and outcomes in postpancreaticoduodenectomy pancreaticocutaneous fistula. J Gastrointest Surg 8 (2004) 951-959
3. Bartoli F.G., Arnone G.B., Ravera G., and Bachi V. Pancreatic fistula and relative mortality in malignant disease after pancreaticoduodenectomy. Review and statistical meta-analysis regarding 15 years of literature. Anticancer Res 11 (1991) 1831-1848
4. Tsiotos G.G., Farnell M.B., and Sarr M.G. Are the results of pancreatectomy for pancreatic cancer improving?. World J Surg 23 (1999) 913-919
5. Bassi C., Falconi M., Salvia R., et al. Management of complications after pancreaticoduodenectomy in a high volume centre: Results on 150 consecutive patients. Dig Surg 18 (2001) 453-458
6. Cameron J.L., Riall T.S., Coleman J., and Belcher K.A. One thousand consecutive pancreaticoduodenectomies. Ann Surg 244 (2006) 10-15
7. Poon R.T., Lo S.H., Fong D., et al. Prevention of pancreatic anastomotic leakage after pancreaticoduodenectomy. Am J Surg 183 (2002) 42-52
8. Yeo C.J., Cameron J.L., Sohn T.A., et al. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: Pathology, complications, and outcomes. Ann Surg 226 (1997) 248-257
9. Balcolm J.H., Rattner D.W., Warshaw A.L., et al. Ten-year experience with 733 pancreatic resections: Changing indications, older patients, and decreasing length of hospitalization. Arch Surg 136 (2001) 391-398
10. Gouma D.J., van Geenen R.C., van Gulik T.M., et al. Rates of complications and death after pancreaticoduodenectomy: risk factors and the impact of hospital volume. Ann Surg 232 (2000) 786-795
11. Pratt W.B., Maithel S.K., Vanounou T., et al. Clinical and economic validation of the International Study Group of Pancreatic Fistula (ISGPF) classification scheme. Ann Surg 245 (2007) 443-451
12. Pratt W.B., Maithel S.K., Vanounou T., et al. Postoperative pancreatic fistulas are not equivalent after proximal, distal, and central pancreatectomy. J Gastrointest Surg 10 (2006) 1264-1279
13. Buchler M., Friess H., Klempa I., et al. Role of octreotide in the prevention of postoperative complications following pancreatic resection. Am J Surg 163 (1992) 125-130
14. Pederzoli P., Bassi C., Falconi M., and Camboni M.G. Efficacy of octreotide in the prevention of complications of elective pancreatic surgery. Br J Surg 81 (1994) 265-269
15. Rosenberg L., MacNeil P., and Turcotte L. Economic evaluation of the use of octreotide for prevention of complications following pancreatic resection. J Gastrointest Surg 3 (1999) 225-232
16. Lowy A.M., Lee J.E., Pisters P.W., et al. Prospective, randomized trial of octreotide to prevent pancreatic fistula after pancreaticoduodenectomy for malignant disease. Ann Surg 226 (1997) 632-641
17. Yeo C.J., Cameron J.L., Lillemoe K.D., et al. Does prophylactic octreotide decrease the rates of pancreatic fistula and other complications after pancreaticoduodenectomy?. Results of a prospective randomized placebo-controlled trial. Ann Surg 232 (2000) 419-429
18. de la Medina A., and Sarr M.G. Somatostatin analogues in the prevention of pancreas-related complications after pancreatic resection. HPB 13 (2006) 190-193
19. Barnett S.P., Hodul P.J., Creech S., et al. Octreotide does not prevent postoperative pancreatic fistula or mortality following pancreaticoduodenectomy. Am Surg 70 (2004) 222-227
20. Gyr K.E., and Meier R. Pharmacodynamic effects of sandostatin in the gastrointestinal tract. Digest 54 Suppl 1 (1993) 14-19
21. Harris A.G. Somatostatin and somatostatin analogues: pharmacokinetics and pharmacodynamic effects. Gut 35 (1994) S1-S4
22. Henegouwen M.I., Gulik T.M., Akkermans L.M.A., et al. The effect of octreotide on gastric emptying at a dosage used to prevent complications after pancreatic surgery: a randomised, placebo controlled study in volunteers. Gut 41 (1997) 758-762
23. Konstadoulakis M.M., Filippakis G.M., Lagoudianakis E., et al. Intraarterial bolus octreotide administration during Whipple procedure in patients with fragile pancreas: a novel technique for safer pancreaticojejunostomy. J Surg Oncol 89 (2005) 268-272
24. Foitzik T., Gock M., Schramm C., et al. Octreotide hardens the pancreas. Langenbecks Arch Surg 391 (2006) 108-112
25. Klempa J., Schwedes U., and Usadel K.H. Prevention of postoperative pancreatic complications following duodenopancreatectomy using somatostatin. Chirurg 50 (1979) 427-431
26. Bassi C., Dervenis C., Butturini G., et al. Postoperative pancreatic fistula: An international study group (ISGPF) definition. Surgery 138 (2005) 8-13
27. Matsusue S., Takeda H., Nakamura Y., et al. A prospective analysis of factors influencing pancreaticojejunostomy performed using a single method, in 100 consecutive pancreaticoduodenectomies. Surg Today 28 (1998) 719-726
28. Yeh T.S., Jan Y.Y., Jeng L.B., et al. Pancreaticojejunal anastomotic leak after pancreaticoduodenectomy-multivariate analysis of perioperative risk factors. J Surg Res 67 (1997) 119-125
29. Al Sharaf C., Ishe I., Dawiskiba S., and Andren-Sandberg A. Characteristics of the gland remant predict complication after subtotal pancreaticoduodenectomy. Dig Surg 14 (1997) 101-106
30. Sato N., Yamaguchi K., Chijiiwa K., and Tanaka M. Risk analysis of pancreatic fistula after pancreatic head resection. Arch Surg 133 (1998) 1094-1098
31. Vanounou T., Pratt W.B., Fischer J.E., et al. Deviation Based Cost Modeling (DBCM): a generalizable model to evaluate the clinical and economic impact of clinical pathways. J Am Coll Surg 204 (2007) 570-579
32. Dindo D., Demartines N., and Clavien P.A. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240 (2004) 205-213
33. DeOliveira M.L., Winter J.M., Schafer M., et al. Assessment of complications after pancreatic surgery: a novel grading system applied to 633 patients undergoing pancreaticoduodenectomy. Ann Surg 244 (2006) 931-939
34. Copeland G.P., Jones D., and Walters M. POSSUM: a scoring system for surgical audit. Br J Surg 78 (1991) 356-360
35. Bloom S.R., Mortimer C.H., Thorner M.O., et al. Inhibition of gastrin- and gastric acid secretion by growth hormone release inhibiting hormone. Lancet 2 (1974) 1106-1109
36. Raptis S., Schlegel W., Lehmann E., et al. Effects of somatostatin on the exocrine pancreas and the release of duodenal hormones. Metabolism 27 (1978) 1321-1328